PL356423A1 - Nowa krystaliczna postać kwasu N-[4-[2-(2-amino-4,7-dihydro-4-okso-3H-pirolo[2,3-d]-pirymidyn-5-ylo)-etylo]-benzoilo]-L-glutaminowego i proces jej przygotowania - Google Patents

Nowa krystaliczna postać kwasu N-[4-[2-(2-amino-4,7-dihydro-4-okso-3H-pirolo[2,3-d]-pirymidyn-5-ylo)-etylo]-benzoilo]-L-glutaminowego i proces jej przygotowania

Info

Publication number
PL356423A1
PL356423A1 PL01356423A PL35642301A PL356423A1 PL 356423 A1 PL356423 A1 PL 356423A1 PL 01356423 A PL01356423 A PL 01356423A PL 35642301 A PL35642301 A PL 35642301A PL 356423 A1 PL356423 A1 PL 356423A1
Authority
PL
Poland
Prior art keywords
pyrrolo
pyrimidin
dihydro
benzoyl
oxo
Prior art date
Application number
PL01356423A
Other languages
English (en)
Other versions
PL208061B1 (pl
Inventor
Erik Christopher Chelius
Susan Marie Reutzel-Edens
Den Berghe Snorek Sharon Van
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL356423(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL356423A1 publication Critical patent/PL356423A1/pl
Publication of PL208061B1 publication Critical patent/PL208061B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
PL356423A 2000-02-25 2001-02-12 Postać krystaliczna heptahydratu soli disodowej kwasu N-[4-[2-(2-amino-4,7-dihydro-4-okso-3H-pirolo [2,3-d]-pirymidyn-5-ylo) etylo] benzoilo]-L-glutaminowego i jej zastosowanie PL208061B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25
PCT/US2001/001229 WO2001062760A2 (en) 2000-02-25 2001-02-12 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Publications (2)

Publication Number Publication Date
PL356423A1 true PL356423A1 (pl) 2004-06-28
PL208061B1 PL208061B1 (pl) 2011-03-31

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
PL356423A PL208061B1 (pl) 2000-02-25 2001-02-12 Postać krystaliczna heptahydratu soli disodowej kwasu N-[4-[2-(2-amino-4,7-dihydro-4-okso-3H-pirolo [2,3-d]-pirymidyn-5-ylo) etylo] benzoilo]-L-glutaminowego i jej zastosowanie

Country Status (35)

Country Link
US (1) US7138521B2 (pl)
EP (1) EP1259513B1 (pl)
JP (1) JP4846158B2 (pl)
KR (1) KR100744917B1 (pl)
CN (1) CN1183135C (pl)
AR (1) AR029471A1 (pl)
AT (1) ATE249462T1 (pl)
AU (1) AU777047B2 (pl)
BR (1) BR0108604A (pl)
CA (1) CA2400155C (pl)
CO (1) CO5261585A1 (pl)
CZ (1) CZ303772B6 (pl)
DE (1) DE60100750T2 (pl)
DK (1) DK1259513T3 (pl)
DZ (1) DZ3283A1 (pl)
EA (1) EA004684B1 (pl)
EG (1) EG24073A (pl)
ES (1) ES2206403T3 (pl)
HR (1) HRP20020701B1 (pl)
HU (1) HU229704B1 (pl)
IL (2) IL150480A0 (pl)
MX (1) MXPA02008242A (pl)
MY (1) MY124784A (pl)
NO (1) NO323422B1 (pl)
NZ (1) NZ519796A (pl)
PE (1) PE20011082A1 (pl)
PL (1) PL208061B1 (pl)
PT (1) PT1259513E (pl)
SI (1) SI1259513T1 (pl)
SK (1) SK287375B6 (pl)
SV (1) SV2002000321A (pl)
TW (1) TWI237024B (pl)
UA (1) UA72791C2 (pl)
WO (1) WO2001062760A2 (pl)
ZA (1) ZA200205265B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
AU2006311820A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and erlotinib for treating cancer
JP2009514889A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法
DE602007011384D1 (de) * 2006-08-14 2011-02-03 Sicor Inc Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure
KR101045616B1 (ko) * 2006-08-14 2011-07-01 시코르, 인크. 페메트렉세드 이산의 결정형 및 이의 제조 방법
KR20090052355A (ko) 2006-08-14 2009-05-25 시코르, 인크. 순도가 높은 페메트렉세드 이산 및 이의 제조 방법
WO2008021385A2 (en) 2006-08-14 2008-02-21 Sicor Inc. Processes for preparing intermediates of pemetrexed
CA2667348A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
MX2009010568A (es) * 2007-04-03 2009-10-22 Reddys Lab Ltd Dr Formas solidas de pemetrexed.
CN101417998B (zh) * 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
US20090181990A1 (en) * 2007-12-23 2009-07-16 Patel Nileshkumar S Stable amorphous form of pemetrexed disodium
WO2010028105A2 (en) * 2008-09-08 2010-03-11 Dr. Reddy's Laboratories Ltd. Amorphous pemetrexed disodium
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
EP2504341A1 (en) 2009-11-24 2012-10-03 Azad Pharmaceutical Ingredients AG A new crystalline form of pemetrexed disodium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
CA2827455C (en) * 2011-03-25 2017-10-24 Scinopharm Taiwan Ltd Process for the production of a pemetrexed salt
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (en) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Crystalline pemetrexed dipotassium process
ZA201400898B (en) 2013-02-06 2015-12-23 Cipla Ltd Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
US20160051679A1 (en) 2013-04-12 2016-02-25 Actavis Group Ptc Ehf. Pemetrexed Formulation
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
US20160145260A1 (en) 2013-06-14 2016-05-26 Synthon B.V. Stable pemetrexed arginine salt and compositions comprising it
WO2015008221A1 (en) 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Novel crystalline forms of pemetrexed tromethamine salts
JP6313317B2 (ja) 2013-10-03 2018-04-18 富士フイルム株式会社 注射液製剤及びその製造方法
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
CA2962383C (en) * 2014-10-30 2019-10-08 Scinopharm Taiwan, Ltd. Crystalline forms of pemetrexed diacid and manufacturing processes therefor
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
WO2019073482A1 (en) * 2017-10-10 2019-04-18 Sun Pharmaceutical Industries Limited INTRAVENOUS INFUSION TYPE DOSAGE FORM FOR PETREXED
EP3749311A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
WO2025244944A1 (en) * 2024-05-20 2025-11-27 Opna Bio SA Crystal forms of an agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) * 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
CA2263907A1 (en) * 1996-08-30 1998-03-05 Christopher Leighon Jordan Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
CN1246295C (zh) * 1997-09-26 2006-03-22 伊莱利利公司 用于制造抗叶酸剂的方法和中间体
EP1212325A2 (en) * 1999-08-23 2002-06-12 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Also Published As

Publication number Publication date
MY124784A (en) 2006-07-31
AU777047B2 (en) 2004-09-30
NO20023974D0 (no) 2002-08-21
SK11862002A3 (sk) 2003-01-09
EA004684B1 (ru) 2004-06-24
JP4846158B2 (ja) 2011-12-28
DE60100750D1 (de) 2003-10-16
PT1259513E (pt) 2004-02-27
US20030216416A1 (en) 2003-11-20
IL150480A0 (en) 2002-12-01
NO323422B1 (no) 2007-04-30
UA72791C2 (uk) 2005-04-15
PL208061B1 (pl) 2011-03-31
EA200200905A1 (ru) 2003-02-27
EP1259513B1 (en) 2003-09-10
KR20020075449A (ko) 2002-10-04
DE60100750T2 (de) 2004-07-29
CZ303772B6 (cs) 2013-05-02
NO20023974L (no) 2002-08-21
WO2001062760A2 (en) 2001-08-30
DK1259513T3 (da) 2004-01-12
PE20011082A1 (es) 2001-10-22
SV2002000321A (es) 2002-07-16
CO5261585A1 (es) 2003-03-31
HU229704B1 (en) 2014-05-28
CN1406238A (zh) 2003-03-26
HRP20020701B1 (en) 2011-02-28
US7138521B2 (en) 2006-11-21
CA2400155A1 (en) 2001-08-30
ATE249462T1 (de) 2003-09-15
KR100744917B1 (ko) 2007-08-01
TWI237024B (en) 2005-08-01
DZ3283A1 (fr) 2001-08-30
NZ519796A (en) 2003-01-31
WO2001062760A3 (en) 2001-12-06
MXPA02008242A (es) 2002-11-29
EG24073A (en) 2008-05-11
SI1259513T1 (en) 2003-12-31
AU3445101A (en) 2001-09-03
HUP0204232A2 (hu) 2003-04-28
HRP20020701A2 (en) 2003-12-31
ZA200205265B (en) 2003-11-11
BR0108604A (pt) 2002-11-19
HUP0204232A3 (en) 2006-01-30
IL150480A (en) 2007-12-03
CA2400155C (en) 2009-09-15
CZ20022875A3 (cs) 2003-02-12
ES2206403T3 (es) 2004-05-16
JP2003530321A (ja) 2003-10-14
AR029471A1 (es) 2003-07-02
SK287375B6 (sk) 2010-08-09
HK1051856A1 (en) 2003-08-22
EP1259513A2 (en) 2002-11-27
CN1183135C (zh) 2005-01-05

Similar Documents

Publication Publication Date Title
IL150480A0 (en) A NOVEL-CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4, 7-DIHYDRO-4-OXO-3H-PYRROLO[2, 3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR
AU6890800A (en) A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
PL373679A1 (pl) Sposoby otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
HUP1300386A2 (en) New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
TWI377063B (en) Crystalline forms of pemetrexed diacid and processes for the preparation thereof
NO2014030I1 (no) (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.
HUP0303350A3 (en) Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions
CA2031890A1 (en) N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
AU7288100A (en) Regulation of secondary metabolite production
AU2002338695A1 (en) Crystalline hydrates of nicotinic acid anilide and benzoyl anilide derivatives
IL160640A0 (en) Crystalline hydrates of nicotinic acid anilide and benzoyl anilide derivatives
HUP0402253A3 (en) Process for the purification of n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-phenyl]-n-ethylacetamide(zaleplon) and the preparation of its novel crystalline forms and pharmaceutical compositions containing the latters
WO2001017959A3 (en) Vitronectin receptor antagonists
IL150403A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
AU2001291233A1 (en) Polymorphs of pioglitazone hydrochloride and their use as antidiabetics
IL157061A (en) Process and intermediates for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl)piperazin -1-yl)-methanone and salts thereof
IL150402A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
AU2003224361A1 (en) Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid
AU2001296746A1 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
AU2002213119A1 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and vinorelbine and method of using the same
PL337788A1 (en) Method of obtaining 1-{[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazole[3,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl}-4-methylpiperazine
AU5297296A (en) Piperidine derivatives as diuretic
AU2002230022A1 (en) Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
IL140127A0 (en) Process for the preparation of optically active 1,4-benzodixoane-2-carboxylic acid and derivatives thereof
AU2002255007A1 (en) Process for the fermentative preparation of d-pantothenic acid and/or salts thereof